DK1068238T3 - Integrinheterodimer og subunit deraf - Google Patents

Integrinheterodimer og subunit deraf

Info

Publication number
DK1068238T3
DK1068238T3 DK99919725.4T DK99919725T DK1068238T3 DK 1068238 T3 DK1068238 T3 DK 1068238T3 DK 99919725 T DK99919725 T DK 99919725T DK 1068238 T3 DK1068238 T3 DK 1068238T3
Authority
DK
Denmark
Prior art keywords
rodimes
subunit
integrity unit
integrity
unit
Prior art date
Application number
DK99919725.4T
Other languages
English (en)
Inventor
Evy Lundgren-Akerlund
Original Assignee
Xintela Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801164A external-priority patent/SE9801164D0/xx
Priority claimed from SE9900319A external-priority patent/SE9900319D0/xx
Application filed by Xintela Ab filed Critical Xintela Ab
Application granted granted Critical
Publication of DK1068238T3 publication Critical patent/DK1068238T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
DK99919725.4T 1998-04-02 1999-03-31 Integrinheterodimer og subunit deraf DK1068238T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801164A SE9801164D0 (sv) 1998-04-02 1998-04-02 Integrin subinit alfa10
SE9900319A SE9900319D0 (sv) 1999-01-28 1999-01-28 The integrin subunit alfa10, an antiadhesive target
PCT/SE1999/000544 WO1999051639A1 (en) 1998-04-02 1999-03-31 An integrin heterodimer and a subunit thereof

Publications (1)

Publication Number Publication Date
DK1068238T3 true DK1068238T3 (da) 2013-01-14

Family

ID=26663256

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99919725.4T DK1068238T3 (da) 1998-04-02 1999-03-31 Integrinheterodimer og subunit deraf

Country Status (8)

Country Link
US (5) US7029858B1 (da)
EP (1) EP1068238B1 (da)
JP (3) JP4912528B2 (da)
AU (1) AU761430B2 (da)
CA (1) CA2324381C (da)
DK (1) DK1068238T3 (da)
ES (1) ES2396693T3 (da)
WO (1) WO1999051639A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1068238T3 (da) * 1998-04-02 2013-01-14 Xintela Ab Integrinheterodimer og subunit deraf
US20030055231A1 (en) 1998-10-28 2003-03-20 Jian Ni 12 human secreted proteins
SE9902056D0 (sv) * 1999-06-03 1999-06-03 Active Biotech Ab An integrin heterodimer and an alpha subunit thereof
AU2003239016B2 (en) * 2002-06-14 2007-09-20 Xintela Ab Marker for stem cells and its use
JP2006510576A (ja) * 2002-06-17 2006-03-30 カルテラ、アクチボラグ アテローム性動脈硬化症のプラーク形成の進行を防止するためのインテグリンα１０鎖の方法および使用
SE0301087D0 (sv) 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
JP5064025B2 (ja) * 2003-04-14 2012-10-31 キシンテラ、アクチボラグ インテグリンα１０β１を結合することができる新規モノクローナル抗体
WO2005118809A2 (en) * 2004-04-29 2005-12-15 The University Of North Carolina At Chapel Hill Methods and compositions for enhancing cell adhesion properties
WO2008068481A1 (en) * 2006-12-05 2008-06-12 Cartela R & D Ab New compounds, methods and uses
WO2008072000A2 (en) * 2006-12-15 2008-06-19 Xintela Ab (Se) Use of integrin alpha 10 binding antibody to modulate extracellular matrix ( cartilage) turnover
ES2850048T3 (es) 2015-02-16 2021-08-25 Xintela Ab Detección y tratamiento de tumores malignos en el SNC
CN108341853B (zh) * 2017-01-22 2022-06-21 中国科学院化学研究所 人血清白蛋白特异性识别多肽及其应用
AU2018281280B2 (en) 2017-06-07 2024-12-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
CN111032859B (zh) 2017-06-29 2024-02-27 辛特拉股份公司 软骨细胞的质量保证
CN112040985A (zh) 2018-02-07 2020-12-04 瑞泽恩制药公司 用于递送治疗性蛋白质的方法和组合物
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
SG11202110729TA (en) 2019-04-15 2021-10-28 Xintela Ab Integrin alpha10 and aggressive cancer forms

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
EP0330506A3 (en) * 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US5310874A (en) * 1991-05-03 1994-05-10 The Scripps Research Institute Integrin α subunit cytoplasmic domain polypeptides and antibodies
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
EP0635029A4 (en) * 1992-04-10 1996-01-24 Gen Hospital Corp MATRIX PROTEIN FROM CARTILAGE AND APPLICATION METHODS.
AU6639394A (en) * 1993-04-26 1994-11-21 Children's Medical Center Corporation A method for rapid formation and isolation of focal adhesion complexes
US5853987A (en) * 1995-04-24 1998-12-29 The Texas A & M University System Decorin binding protein compositions and methods of use
WO1997031653A1 (en) 1996-03-01 1997-09-04 Beth Israel Deaconess Medical Center Diagnosis and treatment of metastic breast carcinoma
US5843436A (en) 1996-04-22 1998-12-01 The Trustees Of Columbia University, In The City Of New York Method of preventing and treating bacterial infection of sutures and prosthetic devices, and promoting ingress of leukocytes into tumor foci
US6046316A (en) * 1997-12-09 2000-04-04 Wayne State University Nucleic acid encoding truncated integrins
DK1068238T3 (da) * 1998-04-02 2013-01-14 Xintela Ab Integrinheterodimer og subunit deraf
JP2001354699A (ja) 2000-06-12 2001-12-25 Teijin Ltd アンギオテンシンｉｉと結合する抗体
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
EP1496886A1 (en) * 2002-04-12 2005-01-19 Cartela AB Knockout mice and their use
AU2003239016B2 (en) * 2002-06-14 2007-09-20 Xintela Ab Marker for stem cells and its use
SE0301087D0 (sv) * 2003-04-14 2003-04-14 Cartela Ab New monoclonal antibody
JP5064025B2 (ja) * 2003-04-14 2012-10-31 キシンテラ、アクチボラグ インテグリンα１０β１を結合することができる新規モノクローナル抗体

Also Published As

Publication number Publication date
JP2002517182A (ja) 2002-06-18
US10081666B2 (en) 2018-09-25
US7029858B1 (en) 2006-04-18
US20060178503A1 (en) 2006-08-10
JP5650038B2 (ja) 2015-01-07
US20180079795A9 (en) 2018-03-22
JP2014221055A (ja) 2014-11-27
AU761430B2 (en) 2003-06-05
JP4912528B2 (ja) 2012-04-11
AU3738099A (en) 1999-10-25
US8895253B2 (en) 2014-11-25
JP2011217745A (ja) 2011-11-04
US8048991B2 (en) 2011-11-01
CA2324381A1 (en) 1999-10-14
US20170121386A1 (en) 2017-05-04
WO1999051639A1 (en) 1999-10-14
US20130137118A1 (en) 2013-05-30
CA2324381C (en) 2013-02-26
US20120136141A1 (en) 2012-05-31
EP1068238A1 (en) 2001-01-17
ES2396693T3 (es) 2013-02-25
EP1068238B1 (en) 2012-10-03

Similar Documents

Publication Publication Date Title
DK1454907T3 (da) Quninazolin og pyridopyrmidin-derivativer
NO991151D0 (no) Forbindelse og anvendelse derav
IS6411A (is) Kaspasa tálmar og notkun þeirra
IS5525A (is) Innúðabúnaður og aðferð
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
DK0815861T3 (da) Sulfonamider og anvendelse deraf
NO20021449D0 (no) Substituerte 2-tio-3,5-dicyano-4-aryl-6-aminopyridiner og anvendelse derav
IS4481A (is) Díhýdrópyramídín og notkun þeirra
NO20014560D0 (no) Quinasoliner og terapautisk anvendelse derav
NO20006488D0 (no) Sammensetning og anvendelse
NO20010442D0 (no) Lysledende anordning og fremgangsmåte
NO995811D0 (no) Selvgjenopprettende og selvbekreftende kryptosystemer
NO20004274D0 (no) Proteaseaktivert reseptor 4 og anvendelse derav
NO20003916D0 (no) Benzotiadiazoler og derivater
DE59706609D1 (de) Spannstock
DK1140952T3 (da) Phosphororganiske forbindelser og anvendelse heraf
NO20005502D0 (no) Polymerer og deres anvendelse
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
DE60041297D1 (de) Empfangsgerät und- Verfahren
NO983159L (no) Koblingsanordning og koblingsbeslag
NO20000493D0 (no) Sveisemateriale og anvendelse derav
DK0936968T3 (da) Forbindelsesindretning og forbindelsesfremgangsmåde
DE59812220D1 (de) Halte- und trageband
NO306663B1 (no) Opplagringsanordning og lagerenhet